Background: Campylobacter spp. are leading foodborne pathogens, with increasing antimicrobial resistance (AMR) posing a critical public health threat. While broiler chickens have been widely studied, turkeys represent an underexplored reservoir. The present study investigates Campylobacter spp. in turkeys, focusing on isolation frequency, resistance, and virulence within the context of One Health. Methods: A total of 182 cecal samples were collected from slaughtered turkeys in Romania. Isolation and identification of Campylobacter jejuni and C. coli followed ISO 10272-1:2017 guidelines. Antimicrobial susceptibility testing was conducted via broth microdilution, and molecular analyses using PCR targeted species identification, resistance determinants, and virulence-associated genes. Results: Campylobacter spp. were detected in 75.8% of samples, with C. jejuni and C. coli accounting for 54.3% and 45.7%, respectively. High resistance rates were observed to ciprofloxacin (89.9%) and tetracycline (85.5%), with moderate resistance to erythromycin and ertapenem. No resistance was found to gentamicin or chloramphenicol. Genotypic analyses confirmed the presence of resistance genes (e.g., tetO, gyrA—Thr-86-Ile mutation, ermB, cmeB) and widespread virulence genes (flaA, cadF, cdtAB, ciaB), supporting phenotypic results. Conclusions: The survey highlights turkeys as a significant but neglected source of resistant and virulent Campylobacter spp., with implications for food safety and public health. The convergence of AMR and virulence aspects calls for integrated surveillance and control strategies across veterinary and human health sectors, supporting the One Health strategy.

Canine leishmaniasis is an emerging threat in Europe shaped by ecological, climatic, and socio-economic factors. This systematic review examines the prevalence of Leishmania spp. infection in dogs, based on information collected from studies published between 2015 and 2024 across 14 European countries. Available data was compiled and analyzed following PRISMA guidelines, revealing pronounced geographical variability. Prevalence was highest in southern European countries such as Portugal, Italy, and Greece, while substantially lower rates were reported in Central and Northern Europe. Despite differences in diagnostic approaches and surveillance intensity across countries, overall patterns point to endemic transmission in southern regions and a growing epidemiological risk in areas traditionally considered non-endemic. These findings underscore the need for harmonized diagnostic protocols and a strengthened surveillance network, consistent with the One Health framework, to enable effective responses to climate change and the shifting landscape of vector-borne diseases in Europe.

Background/Objectives: Staphylococcus aureus is a major pathogen of concern in raw milk due to its potential to cause foodborne illness and its increasing antimicrobial resistance (AMR). In Romania, data on the occurrence and resistance patterns of S. aureus in raw sheep milk from traditional farming systems remain limited. This study investigated the presence and antimicrobial resistance of S. aureus in 106 raw sheep milk samples collected from traditional farms in the Banat region of western Romania. Methods: Coagulase-positive staphylococci (CPS) were enumerated using ISO 6888-1:2021 protocols. Isolates were identified at the species level using the Vitek 2 system and molecularly confirmed via PCR targeting the 16S rDNA and nuc genes. Methicillin resistance was assessed by detecting the mecA gene. Antimicrobial susceptibility was determined using the Vitek 2 AST-GP79 card. Results: CPS were detected in 69 samples, with S. aureus confirmed in 34.9%. The mecA gene was identified in 13.5% of S. aureus isolates, indicating the presence of methicillin-resistant S. aureus (MRSA). Resistance to at least two antimicrobials was observed in 97.3% of isolates, and 33 strains (89.2%) met the criteria for multidrug resistance (MDR). The most frequent MDR phenotype involved resistance to lincomycin, macrolides, β-lactams, tetracyclines, and aminoglycosides. Conclusions: The high prevalence of S. aureus, including MRSA and MDR strains, in raw sheep milk from traditional farms represents a potential public health risk, particularly in regions where unpasteurized dairy consumption persists. These findings underscore the need for enhanced hygiene practices, prudent antimicrobial use, and AMR monitoring in small-scale dairy systems.

Enterocytozoon bieneusi is the most frequently diagnosed microsporidian parasite in humans and a recognized cause of diarrheal disease, particularly in immunocompromised individuals. Its broad host range, which includes livestock, companion animals, and wildlife, highlights its zoonotic potential and warrants careful epidemiological assessment. This narrative review synthesizes available data on the occurrence and genetic diversity of E. bieneusi in European domestic ungulates (cattle, pigs, sheep, goats, horses, and water buffaloes) and pets (dogs and cats), aiming to provide an integrated perspective on animal reservoirs and their relevance for public health. Publications retrieved from the Web of Science Core Collection database were systematically screened, and country-specific results were extracted, emphasizing prevalence rates, genotype distributions, and zoonotic implications. Across Europe, cattle and pigs emerged as the most studied hosts, frequently harboring zoonotic group 1 genotypes such as I, J, BEB4, BEB6, and EbpA, while small ruminants, horses, and buffaloes remain comparatively undocumented. In pets, the dog-adapted genotype PtEb IX was predominant, but several zoonotic genotypes were also identified. Overall, the current evidence confirms the wide host range of E. bieneusi in Europe but also reveals significant data gaps compared to regions such as China, underlining the need for broader surveillance and harmonized molecular approaches within a One Health framework.

Subclinical mastitis is a major but often overlooked constraint to dairy productivity, causing economic losses through reduced milk yield and quality. In Romania, comprehensive data on the bacterial etiology and antimicrobial resistance (AMR) of subclinical mastitis are limited. This study aimed to characterize the etiological agents and antimicrobial susceptibility profiles of major bacterial pathogens isolated from subclinical mastitis cases in dairy cows from Western Romania. Between 2021 and 2022, milk samples were collected from 117 lactating cows diagnosed with subclinical mastitis on three dairy farms. Bacterial isolation and differentiation were performed on ChromID^® CPS^® Elite Agar, and isolates were confirmed by standard biochemical tests. Antimicrobial susceptibility testing of Staphylococcus aureus and Escherichia coli isolates was conducted using the automated Vitek^®2 system, interpreted according to CLSI veterinary standards. Multidrug resistance (MDR) was defined as resistance to at least one agent in three or more antimicrobial classes. Bacterial growth occurred in 51 of 117 samples (43.6%). S. aureus subsp. aureus predominated (28.2%), followed by E. coli (4.3%), Klebsiella pneumoniae subsp. pneumoniae (2.3%), and Streptococcus uberis (2.3%). Mixed infections occurred in 6.0% of positive samples. Among S. aureus, the highest resistance rates were to fosfomycin (58.3%), penicillin (44.4%), clindamycin (44.4%), and tetracycline (41.7%), with 47.2% MDR isolates. E. coli showed resistance to amoxicillin/clavulanic acid (88.9%), ampicillin (55.6%), and cefotaxime (55.6%), with 66.6% MDR. S. aureus remains the leading cause of subclinical mastitis in Western Romania. The high MDR rates highlight the need for targeted antimicrobial stewardship, culture-based therapy, and continuous AMR monitoring under the “One Health” framework.

Type 2 diabetes mellitus (T2DM) is a major global health challenge that has intensified interest in multi-target nutraceuticals with potential adjunctive benefits. Ganoderma lucidum (Lingzhi/Reishi) is a medicinal mushroom traditionally used in East Asia and is increasingly investigated for its role in glycemic regulation and metabolic disturbances. This review critically synthesizes current evidence on its hypoglycemic effects, focusing on bioactive compounds, molecular mechanisms, and translational limitations. Unlike broader reviews on Ganoderma bioactivity and health-related benefits, this review specifically evaluates the alignment between taxonomic authentication, chemical standardization, preclinical mechanisms, and human clinical evidence in the context of glycemic regulation. This narrative review was based on a targeted literature search conducted in PubMed/MEDLINE, Web of Science, and Scopus for studies published up to October 2025, supplemented by Google Scholar. The included studies comprised in vitro experiments, in vivo animal models, and human clinical trials evaluating glycemic and metabolic outcomes of Ganoderma preparations. In vitro and animal studies indicate that polysaccharides, including β-(1→3)/(1→6)-glucans and proteoglycans such as FYGL, may improve insulin sensitivity via AMPK (AMP-activated protein kinase) and PI3K/Akt pathways, promote GLUT4 (glucose transporter type 4) translocation, suppress hepatic gluconeogenesis, protect pancreatic β-cells, and modulate gut microbiota. In enzyme assays and preclinical models, lanostane-type triterpenoids act primarily by inhibiting α-glucosidase and α-amylase, thereby potentially reducing postprandial glucose excursions. Despite consistent preclinical evidence, clinical findings remain heterogeneous, with the largest randomized controlled trial reporting no significant glycemic benefit. Overall, Ganoderma lucidum shows strong mechanistic plausibility but insufficient clinical evidence for antidiabetic efficacy. Future research should prioritize species authentication, chemical standardization, and adequately powered clinical trials.